PMA device
StarClose SE® Vascular Surgical System
Abbott Vascular Devices · Device, Hemostasis, Vascular (MGB, Class III) · First FDA decision Oct 9, 2015, newest Dec 9, 2025Vascular access
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
PMA pathway
Device trials
0
Naming "StarClose SE"
MAUDE reports
2,795
Brand "StarClose SE", since 2015
PubMed studies
14
Mentioning "StarClose SE"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing StarClose SE® Vascular Surgical System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
- StarClose SE® Vascular Surgical SystemPMA supplement
P050007-S047 · Decided Dec 9, 2025 · 211 days after receipt · Normal 180 Day Track No User Fee
Device type: Device, hemostasis, vascular (MGB) · Cardiology
- StarClose SE Vascular Surgical SystemPMA supplement
P050007-S046 · Decided Mar 9, 2025 · 149 days after receipt · Normal 180 Day Track No User Fee
Device type: Device, hemostasis, vascular (MGB) · Cardiology
- StarClose SE® Vascular Surgical SystemPMA supplement
P050007-S045 · Decided Feb 10, 2025 · 157 days after receipt · Normal 180 Day Track No User Fee
Device type: Device, hemostasis, vascular (MGB) · Cardiology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "StarClose SE", any status and sponsor, newest update first.
No registered device study names "StarClose SE".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "StarClose SE", and for the whole product code for context.
This brand
2,795 reports: 261 malfunction, 2,527 injury, 7 death
Whole product code MGB
93,533 reports: 17,154 malfunction, 76,023 injury, 315 death
Newest reports for this brand
- StarClose SE¿Injury
2024168-2026-04123 · Received Oct 26, 2026 · Event dated Sep 15, 2026
Device type: Device, Hemostasis, Vascular (MGB)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hematoma
- StarClose SE¿Injury
2024168-2026-04124 · Received Oct 26, 2026 · Event dated Sep 15, 2026
Device type: Device, Hemostasis, Vascular (MGB)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hematoma
- StarClose SE¿Injury
2024168-2026-04125 · Received Oct 26, 2026 · Event dated Sep 15, 2026
Device type: Device, Hemostasis, Vascular (MGB)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hematoma
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1202-2017 · Started Feb 10, 2017
Reason given: Abbott Vascular is recalling the StarClose SE Vascular Closure System because it may exhibit difficulty or failure to deploy the StarClose SE Clip.
Cause as FDA categorized it: Other · Device type: Device, Hemostasis, Vascular (MGB)
Abbott Vascular-Cardiac Therapies dba Guidant Corporation
Z-1657-2009 · Started May 6, 2009 · Posted by FDA Jul 6, 2009
Reason given: Potential sterility issue. Internal component quarantined for possible contamination, was released for sale after going through sterilization procedure.
Cause as FDA categorized it: Process design · Device type: Device, Hemostasis, Vascular (MGB)
Published research
The most relevant PubMed records for "StarClose SE"[tiab]. The summary above synthesizes these.
- Angioseal VIP® vs. StarClose SE® closure devices: a comparative analysis in non-cardiological procedures.
Lucatelli P, Fanelli F, Cannavale A, et al. · J Cardiovasc Surg (Torino) · 2017Comparative Study
- Central Pseudo-Aneurysm Formation Following Arterial Closure with a StarClose SE Device: When a StarClose Doesn't Completely Close.
Memon S, Ball TC · Am J Case Rep · 2016Case Reports
- Starclose SE® hemostasis after 6F direct antegrade superficial femoral artery access distal to the femoral head for peripheral endovascular procedures in obese patients.
Spiliopoulos S, Kitrou P, Christeas N, et al. · Diagn Interv Radiol · 2016
- Distribution of reported StarClose SE vascular closure device complications in the manufacturer and user facility device experience database.
Johnson DT, Durack JC, Fidelman N, et al. · J Vasc Interv Radiol · 2013Comparative Study
- Safety and efficacy of arterial closure devices in an office-based angiosuite.
Dham S, Ahn S · J Vasc Surg · 2025Comparative Study, Research Support, Non-U.S. Gov't
- Extravascular compared to Intravascular Femoral Closure is Associated with Less Bleeding and Similar MACE after Percutaneous Coronary Intervention.
Kim SH, Behnes M, Baron S, et al. · Int J Med Sci · 2019Comparative Study, Observational Study
- Safety and efficacy of StarClose SE Vascular Closure System in high-risk liver interventional oncology patients.
Gaba RC, Parvinian A, Trinos EM, et al. · J Vasc Access · 2012Evaluation Study
- Differences of bleedings after percutaneous coronary intervention using femoral closure and radial compression devices.
Kim SH, Behnes M, Baron S, et al. · Medicine (Baltimore) · 2019Observational Study
- Access site complications are uncommon with vascular closure devices or manual compression after lower extremity revascularization.
Cheng TW, Farber A, King EG, et al. · J Vasc Surg · 2022Multicenter Study
- Acute limb ischemia caused by incorrect deployment of a clip-based arterial closure device.
Dzieciuchowicz , Zmysowski M, Stefaniak K, et al. · Wideochir Inne Tech Maloinwazyjne · 2016Case Reports
- Nitinol clip distal migration and resultant popliteo-tibial artery occlusion complicating access closure by the StarClose SE vascular closure system.
Choi DH, Kim MJ, Yoo CJ, et al. · BMJ Case Rep · 2016Case Reports
- Nitinol clip distal migration and resultant popliteo-tibial artery occlusion complicating access closure by the StarClose SE vascular closure system.
Choi DH, Kim MJ, Yoo CJ, et al. · J Neurointerv Surg · 2017Case Reports
Other devices of this type
Also filed under product code MGB.
- Angio-Seal Vascular Closure DeviceTerumo Medical Corporation · PMA 2013
- Perclose ProGlide® Suture-Mediated Closure SystemAbbott Vascular, Inc. · PMA 2025
- Mynx Vascular Closure DeviceCordis US Corporation · PMA 2013
- MANTA Vascular Closure DeviceTeleflex Medical, LLC · PMA 2024
- Vascade Vascular Closure System (VCS)Cardiva Medical, Inc. · PMA 2023
- MynxGrip and Mynx Ace Vascular Closure DeviceCordis US Corporation · PMA 2018
- Vascular Solutions Duett Sealing DeviceVascular Solutions, Inc. · PMA 2010
- Angio-Seal Hemostatic Puncture Closure DeviceTerumo Medical Corporation · PMA 2000
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.